Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214628 · ClinicalTrials.gov registry record · Phase 2
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
A Phase 2 study, sponsored by Ophthotech Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT02214628: Clinical Trial Phase 2 study, sponsored by Ophthotech Corporation.
NCT02214628 is a Phase 2 study that was terminated before completion, run by Ophthotech Corporation. The registered enrollment target is 101 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02214628, a Phase 2 study, was terminated before completion, sponsored by Ophthotech Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
Primary Outcome
Number of subjects on either arm with non-serious adverse events (reported by \>5% of subjects)
Interventions
- DRUG Fovista® (anti-PDGF BB) plus anti-VEGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Why NCT02214628 stopped before completion
NCT02214628 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 1 intervention - of which Fovista® (anti-PDGF BB) plus anti-VEGF is the first listed.
NCT02214628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02214628 about?
NCT02214628 is a clinical study titled "Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD". The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
What is the current status of trial NCT02214628?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2014-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02214628?
The interventions under investigation include: Fovista® (anti-PDGF BB) plus anti-VEGF (DRUG).
Who is sponsoring clinical trial NCT02214628?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02214628's enrollment target sits among peer trials
101 672nd of 2000 higher than 1,329 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia